News | January 15, 2026
BioNTech maps pivotal oncology milestones for 2026
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
Sabitha highlighted the growing relevance of minimally invasive therapies in modern medicine
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
The new facility offers an expanded laboratory alongside meeting areas dedicated to development meetings, formulation workshops, and brainstorming sessions
The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
The partnership also sets the stage for broader collaboration on rare disease treatments
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
NGD Infection Prevention was formed to scale the delivery of sequence-based transmission detection
Subscribe To Our Newsletter & Stay Updated
